| Biologic Therapy |
1 |
1 |
| Biosimilars |
0 |
0.99 |
| Health Care Economics |
0 |
0.98 |
| Social Determinants of Health |
0 |
0.08 |
| Exudative ARMD |
0 |
0.04 |
| Health Plans |
0 |
0.04 |
| Retinal Diseases |
0 |
0.04 |
| Health Education and Counseling |
0 |
0.03 |
| Macular Degeneration |
0 |
0.03 |
| Vascular Endothelial Growth Factor |
0 |
0.03 |
| VEGF Inhibitor |
0 |
0.03 |
| Clinical Guidelines |
0 |
0.02 |
| Angiogenesis Inhibitors |
0 |
0.01 |
| Health Care Services |
0 |
0.01 |
| Humanized Monoclonal Antibody |
0 |
0.01 |
| Off-Label Use |
0 |
0.01 |
| Ohio |
0 |
0.01 |
| Ophthalmic |
0 |
0.01 |
| Other Specialty |
0 |
0.01 |
| Retina |
0 |
0.01 |
| Washington |
0 |
0.01 |